🏥 UNH $21.4M Bullish Long Call Roll Up & Out — Whale Locks In $28.6M Aug $400 Profit and Rolls to Dec $450 on Recovery Continuation

Published: May 13, 2026 | Ticker: UNH | Strategy: Long Call Roll Up & Out

---

⚡ Quick Take

At 14:23:49 ET on May 13, a single institutional player executed a textbook long call roll up and out in UnitedHealth Group (NYSE: UNH) — closing 16,868 August 21 $400 calls for $50M in proceeds, then redeploying $21.4M into 8,434 December 18 $450 calls. The net result: $28.6M of profit recycled off the table, with a fresh $21.4M forward commitment that stays long UNH through year-end.

This is NOT a Bear Call Spread. The critical distinction is in the Vol/OI ratios:

• August $400 SELL legs: Vol/OI = 0.77 and 0.18 — both well below 1.0, confirming these are STC (Sell to Close) trades closing existing long inventory, not new short calls being opened.
• December $450 BUY legs: Vol/OI = 0.96 and 0.21 — BTO (Buy to Open), fresh long call positions being established.

A Bear Call Spread would require the SELL legs to be STO (opening new shorts with Vol/OI materially above existing OI). That is not what happened here. The whale took profit on near-dated ITM calls and rolled up $50 in strike and out four months — the same architectural fingerprint as the AMZN roll-up-and-out pattern seen on May 6. The directional read is unambiguously bullish.

Spot at execution: $402.44. New long breakeven: $474.88 (+18.0% from here). Expiry: December 18, 2026 — capturing Q2 earnings (July 10), Q3 earnings (late October), Medicare Advantage open enrollment (Oct 15 – Dec 7), and a likely investor day in late November or early December.

---

🏢 Company Overview

UnitedHealth Group (NYSE: UNH) is the largest U.S. private health insurer and one of the largest health services companies in the world, with a market cap of approximately $365B. The company operates two flagship businesses:

• UnitedHealthcare — the largest Medicare Advantage (MA) carrier by enrollment in the U.S., plus employer and individual health plans. MA is the highest-margin and fastest-growing segment, making CMS rate decisions the single most important external variable for the stock.
• Optum — a diversified health services platform comprising Optum Health (care delivery), Optum Insight (data analytics), and Optum Rx (third-largest pharmacy benefit manager). Optum Rx recently announced a full transition to a transparent, flat fee-based pricing model, pre-empting the most damaging outcomes from federal PBM reform legislation.

UNH trades on the NYSE in the Healthcare / Managed Care sector. After a brutal 12-month stretch that drove shares to a 52-week low of $259 in late March 2026, the stock has staged a +47% recovery — powered by a Q1 2026 earnings beat, a favorable CMS 2027 MA rate finalization, and Optum Rx's regulatory pivot. At $402.44, the stock is essentially at-the-money on the Aug $400 calls the whale just closed, and approximately 12% below the $450 strike on the new December longs.

---

📋 Full Trade Table

All four legs printed simultaneously at 14:23:49 ET on May 13, 2026, spot price $402.44.

Roll Summary:

---

📐 Roll Geometry — Up & Out, Not a Spread

What "Up and Out" Means

The whale moved the strike up $50 (from $400 to $450) and the expiry out four months (August 21 → December 18). This is the defining geometry of a bullish roll: the trader is expressing a view that the underlying will continue to appreciate, and is repositioning the long to a higher, further-dated strike to capture that next leg of the move with reduced capital at risk.

Mechanics at execution:

• The August $400 calls were purchased earlier in 2026 — most likely near the March trough around $259 or during the recovery. With spot at $402.44, those calls are approximately at-the-money to slightly in-the-money (intrinsic ≈$2.44, extrinsic the remainder of the $29.66 option price). The whale sold these calls while they still held significant extrinsic value — $50M across 16,868 contracts.
• The December $450 calls are out-of-the-money ($47.56 OTM, or ≈11.8% above spot). At $24.88/share weighted average, they are priced with substantial extrinsic value given the 219-day runway. The whale paid $21.4M for the right to participate in any move above $474.88 by December 18.

Why This is Definitively NOT a Bear Call Spread

A bear call spread involves:

1. STO (selling to OPEN) a call at a lower strike — collecting premium on a net new short
2. BTO (buying to OPEN) a call at a higher strike — capping the loss on that short

In a bear call spread, the trader profits if the stock stays below the lower strike. The maximum profit is the net credit received. The maximum loss is the spread width minus the credit.

This trade has none of those characteristics:

• The SELL legs are STC (closing longs, not opening shorts). Vol/OI of 0.77 and 0.18 means the volume on May 13 represents 77% and 18% of the existing open interest at that strike, respectively — these are closings against pre-existing long inventory, not new shorts being opened into fresh OI.
• After this trade, the whale has zero short call exposure. They hold only the long December $450 calls.
• The net cash flow is a $28.6M credit from profit-taking, not a credit from a hedged short position.
• The trader's new P&L profile is long gamma, long vega, long delta — exactly the opposite of a short call spread.

Forward Position Metrics

Payoff Profile at December 18 Expiry

P&L per contract (x100)
$15,000 |                                          /
        |                                        /
$10,000 |                                      /
        |                                    /
 $5,000 |                                  /
        |                                /
     $0 |----------------------------/----------  $474.88 breakeven
        |          ($2,488)       /
-$5,000 |________________________/
        $400  $420  $440  $450  $460  $475  $500
                         Spot at expiry

• Below $450: full premium loss ($24.88/share, $2,488/contract, $21.4M aggregate)
• At $474.88: breakeven
• At $500: +$25.12/share, +$2,512/contract, ≈$21.2M aggregate profit
• At $525: +$50.12/share, +$5,012/contract, ≈$42.3M aggregate profit
• At $550: +$75.12/share, +$7,512/contract, ≈$63.4M aggregate profit

---

🔢 Greeks Snapshot (Estimated at Trade Time)

With spot at $402.44, Dec 18 expiry (≈219 DTE), and Dec $450 calls priced at ≈$24.88, the estimated Greeks for the aggregate 8,434-contract position:

Key implications:

• Delta ≈0.38: The position is moderately directional — not as sensitive as ATM calls, but meaningful exposure. The whale gains approximately $1.29M for every $10 move up in UNH.
• Theta ≈-$71,700/day: The 219-day runway provides significant time buffer, but total theta drag over the full period is approximately $15.7M if the stock stays flat — that is 73% of the premium paid. The position needs UNH to move higher, not just hold.
• Vega positive: Any spike in implied volatility (e.g., a macro shock or earnings surprise) benefits the position by increasing the value of the long calls even before intrinsic value is realized.
• Gamma acceleration: As spot approaches $450 (currently 11.8% away), delta will accelerate significantly. If UNH moves to $430–$440, the position becomes increasingly sensitive to further moves — the convexity profile works in the long holder's favor.

---

📈 YTD Chart

UNH spent the first half of 2025 in gradual decline as Medicare Advantage cost trends worsened and MLR guidance deteriorated. The stock capitulated to a 52-week low of $259 in late March 2026 — a level last seen in 2020. The recovery since has been swift: shares are up approximately +47% from the March 2026 trough to current levels near $402.

The August $400 calls the whale just closed were almost certainly purchased near that $259–$280 trough window, which means the original position was deeply in-the-money before being closed. The $50M in proceeds represents a substantial realized gain on an earlier directional bet that the recovery would materialize — which it did.

The new December $450 calls represent the whale's view on the next leg: that the recovery from the H2 2025 trough is not finished, and that the stock will continue to make progress toward pre-2025 levels. The 52-week high before the selloff was approximately $610 (2024 peak); $450 by December 18 would represent a continued recovery but still well below historical highs.

---

🎯 Gamma Support & Resistance

GEX data (captured at 15:04 ET, spot $401.88) shows a clearly bullish dealer positioning structure:

Key GEX Levels:

Net GEX bias: Bullish (total call GEX $115.4 vs. put GEX $24.4 — 4.7:1 ratio). The $400 strike acts as a powerful near-term anchor — the positive GEX there means market makers are long gamma at $400, providing a gravitational pull that tends to keep spot pinned near that level in the near term. The whale closed the August $400 calls INTO that GEX structure, suggesting they were aware of the $400 magnetic effect and are now positioned for a breakout above it via the December $450 longs.

The GEX at $450 ($5.0 net GEX) shows this strike already has notable open interest — consistent with the Vol/OI of 0.96 seen on the larger BTO leg, confirming the whale was buying into an existing strike with real OI depth.

---

📊 Implied Move

The implied move chart reflects the options market's expectation of UNH's price range across upcoming expirations. With spot at $402.10 at the time of the implied move snapshot and the new December $450 long positions established, the key reference points are:

• Q2 earnings (July 10) — the nearest significant catalyst inside the August window the whale just exited. This will be the first test of whether the Q1 MLR improvement (83.9%) was a one-quarter phenomenon or a sustained trend.
• Q3 earnings (late October) — falls inside the December 18 expiry. A second consecutive MLR improvement would materially increase the probability the whale's $450 strike is challenged.
• December 18 expiry — 219 days of optionality, capturing multiple major catalysts.

The Dec $450 calls at $24.88/share imply the market is pricing approximately 6% annualized vol on that wing — consistent with post-recovery vol compression as realized volatility in managed care tends to decrease after the sharp repricing events settle. Elevated implied volatility during the March trough has compressed as confidence in the MLR trajectory grows, which is precisely why the whale chose to roll now: selling the August calls while they retained extrinsic value, before theta decay accelerates into Q2 earnings.

---

📰 Catalysts

🟢 Q1 2026 Earnings Beat — April 21, 2026 (Completed)

UNH reported its strongest quarter in six quarters, per CNBC:

• Revenue: $111.72B vs. $109.57B consensus — a $2.15B beat.
• Adjusted EPS: $7.23 vs. $6.57 consensus — a 10% beat.
• Medical Care Ratio (MLR): 83.9%, down 90 basis points year-over-year from 84.8% in Q1 2025. Per the Q1 2026 UNH earnings release, this is the single most-watched metric in managed care — it measures how much of every premium dollar is paid out in medical claims. A declining MLR means the cost-trend cycle is finally bending.
• FY2026 Adjusted EPS guidance raised from ">$17.75" to ">$18.25", per ad-hoc-news.
• Shares gapped up ≈8% on the day.

The Q1 print is the foundational catalyst for this roll. The whale held the August $400 longs through the April 21 earnings event and was rewarded; closing now locks in that post-earnings appreciation.

🟢 2027 Medicare Advantage Final Rate +2.48% — April 6, 2026

CMS finalized a 2.48% payment rate increase for Medicare Advantage in CY2027, materially above the 0.09% advance notice floated in January, per Home Health Care News. This translates to approximately $4B of incremental 2027 revenue visibility for UNH, according to FinancialContent. The stock surged ≈11% on the announcement.

This rate finalization is now locked in. It provides a durable multi-year tailwind to UNH's largest revenue segment and reduces the binary risk that had been suppressing the multiple for the past 18 months.

🟢 Optum Rx PBM Model Overhaul

Optum Rx announced a full transition to a transparent, flat fee-based pricing model for all clients, eliminating spread pricing ahead of federal delinking provisions in the Consolidated Appropriations Act of 2026, per Modern Healthcare and Healthcare Dive. By moving proactively ahead of the Medicare Part D 100% rebate pass-through requirement, per AJMC, Optum Rx neutralized the most damaging legislative scenario before it materialized. This removes a key regulatory overhang that had weighed on the stock since 2025.

📅 Q2 2026 Earnings — July 10, 2026 (Upcoming)

Confirmed for July 10 (BMO) per the UNH IR site and MarketBeat. This falls inside the August 21 expiry window the whale just exited — meaning they held the August $400 calls through the Q1 print, collected the post-earnings appreciation, and chose to exit ahead of Q2 rather than take on that binary risk again. The new December $450 longs will face this catalyst from a position of no near-term expiry pressure.

Key Q2 watch items: MLR trajectory (will 83.9% hold or revert?), full-year guidance update, and Optum Rx fee-model client retention rates.

📅 Q3 2026 Earnings — Late October 2026 (Upcoming)

Expected mid-to-late October (historically Oct 14–21). Falls inside the December 18 BTO expiry — this is the gating event for the new long-call position. A second consecutive quarter of MLR improvement would be a powerful confirmation of the recovery thesis and a direct catalyst for the stock to challenge $430–$450.

📅 MA Open Enrollment — October 15 – December 7, 2026

Medicare Advantage open enrollment season is a real-time pulse check on UNH's competitive positioning for 2027. Member growth data, plan selections, and any CMS star rating changes during this window will directly inform the 2027 revenue outlook — all landing inside the December 18 expiry.

📅 Potential Investor Day — Late November / Early December 2026

UNH typically hosts a strategic update in late November or early December. If scheduled, this would land directly into the December 18 expiry window, potentially serving as a sentiment-setting event ahead of expiry.

📊 Analyst Consensus

Following the Q1 beat and CMS rate finalization, the analyst upgrade cycle is in motion per MarketBeat:

• Goldman Sachs: PT raised to $435 post-Q1 earnings.
• Argus: Upgraded to Buy, PT $400, per 24/7 Wall St.
• Truist: PT raised to $395; Piper Sandler also raised PT, per Investing.com.
• Consensus: Buy-rated by 26 analysts, average PT ≈$384.50 per MarketBeat.

One notable caveat: consensus PT of $384.50 sits below the current stock price ($402.44), meaning the street has not yet fully caught up to the recovery. The whale's $450 strike implies a more aggressive recovery thesis than the analyst consensus currently supports.

---

💡 Trading Ideas

The whale's roll-up-and-out can serve as an anchor for three different risk profiles.

Idea 1: Retail Variant — Bull Call Spread Dec $400/$450

Profile: Moderate bullish, defined risk, reduced cost basis

Rather than buying naked $450 calls, retail traders can reduce the cost basis by selling the Dec $400 calls against the Dec $450 calls:

• Buy Dec 18 $450 calls (approx. $24.88/share)
• Sell Dec 18 $400 calls (ITM, would collect significant premium — est. $45–$50/share based on current spot relationship)
• Net debit: Approximately $0 to a small net debit (the $400 calls are ITM and rich), or potentially a net credit if the $400 calls are priced above the $450 calls

This spread caps upside at the spread width ($50) minus the net debit, with max profit at $450 or above by December 18. The $400 short leg aligns with the whale's closed position — you're essentially stepping into the role they just vacated on the short side, while the $450 long aligns with their new position.

Note: This is a defined-risk, defined-reward structure. Confirm current bid/ask spreads and liquidity before executing. This is for informational purposes only, not a recommendation.

Idea 2: Momentum Rider — Dec $430 Calls (Closer to ATM)

Profile: More aggressive bullish, higher delta, lower strike

Traders who want more delta exposure can target the Dec $430 calls, which sit between spot ($402.44) and the whale's $450 strike. These will be less expensive than the $400 ITM calls but cheaper than the $450 OTM. The $430 level aligns approximately with the Goldman Sachs $435 price target zone, offering a near-term fundamental anchor.

Key dates: Hold through July 10 Q2 earnings as the primary near-term catalyst.

Idea 3: Conservative Income — Aug $380/$400 Bull Put Spread

Profile: Neutral to mildly bullish, income-oriented

For traders who want yield rather than capital appreciation, selling a bull put spread below current spot can generate premium while the $400 GEX support level does its work. Selling the Aug $400 put and buying the Aug $380 put collects a credit while defining downside. The $400 GEX support (+31.5 net GEX, strongest in the structure) provides a gravitational floor.

Risk: If spot breaks below $400 on an MLR reversal or macro shock, the spread is tested.

---

⚠️ Risk Factors

1. MA Cost Trend Re-acceleration

Q1's 83.9% MLR was favorable, but UNH management explicitly flagged "consistently elevated utilization and unit cost trends" in the Q1 release. A single-quarter MLR improvement is not a confirmed trend. If Q2 shows MLR reverting above 85%, the market reaction would likely be severe — the stock rallied 8% on Q1's improvement, and could give back 10–15% on a reversal. This is the single largest risk to the December $450 long before August 21.

2. PBM Legislative Enforcement

State-level PBM legislation (Indiana SB 140 and others) and federal Part D delinking enforcement could compress Optum Rx margins beyond management guidance, per Modern Healthcare and Healthcare Brew. While Optum Rx's pivot is proactive, implementation costs and client attrition risk remain.

3. Valuation — 55% Rally Already In

The stock has rallied +47% from the March 2026 trough in under two months. At ≈$402 and guidance of ">$18.25" EPS, UNH trades at approximately 22x forward earnings — a premium to managed care peers. The consensus analyst PT of $384.50 implies the stock is already above fair value on current estimates. Gap-down risk on any earnings miss or negative guidance revision is elevated given how far and fast the recovery has moved.

4. Executive Transition & Reputational Risk

The December 2024 Brian Thompson incident and subsequent 2025 management changes created operational and reputational disruption that continues to have tail effects. Ongoing DOJ investigation into MA upcoding practices remains a latent headline risk that could resurface at any point.

5. Options-Specific Risk — Theta Decay & Breakeven Distance

The December $450 calls break even at $474.88 — a +18% move from the May 13 spot of $402.44 is required by December 18 for the position to be profitable at expiry. This is achievable but non-trivial: the stock needs to climb another ≈$72.44 in approximately 219 days. If the stock consolidates or pulls back in the near term, theta decay will erode the value of the $24.88/share premium paid, even if the stock eventually moves higher.

---

🎯 Bottom Line

This is a bullish long call roll up and out, not a spread trade and not a bearish bet. The structural read is unambiguous: a major institution took $50M in realized profit from ITM August $400 calls — calls that were almost certainly purchased near the March 2026 trough — and redeployed $21.4M into December $450 calls, pocketing $28.6M net while maintaining a forward long position through year-end.

The new position tells us:

• The whale is not done — they recycled profit rather than exiting entirely
• The target is higher — moving the strike up $50 signals conviction that $400 is a floor, not a ceiling
• The timeline is extended — December 18 captures every major catalyst remaining in 2026 (Q2, Q3 earnings, open enrollment, potential investor day)

With Goldman Sachs at $435, the 2027 CMS MA rate locked at +2.48%, and Q1 MLR at a multi-year low of 83.9%, the fundamental backdrop supports continued recovery. The risk is real — consensus PT trails spot, the 55% rally has compressed the margin of safety, and Q2 MLR is still an unknown — but the whale's vote is clear: UNH is in recovery, and $450 by December is the next checkpoint.

Catalyst Score: 8/10 — Two earnings prints, the 2027 MA preliminary rate cycle, open enrollment, and a likely investor day all land inside the December 18 window. Score held back from 9–10 by the already-rich recovery rally and consensus PT that currently trails the long strike.

---

📣 Disclosure

This analysis is provided for informational and educational purposes only and does not constitute financial, investment, or trading advice. Options trading involves substantial risk and may result in the loss of the entire premium paid. The strategies described are not suitable for all investors. Past performance of similar trades is not indicative of future results. Always consult a licensed financial professional before making investment decisions. OptionLabs does not hold positions in UNH at the time of publication.